Johnson & Johnson Files 2023 Annual Report on Form 10-K

Ticker: JNJ · Form: 10-K · Filed: Feb 16, 2024 · CIK: 200406

Johnson & Johnson 10-K Filing Summary
FieldDetail
CompanyJohnson & Johnson (JNJ)
Form Type10-K
Filed DateFeb 16, 2024
Risk Levellow
Pages14
Reading Time17 min
Key Dollar Amounts$1.00
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Annual Report, Johnson & Johnson, Financials, Kenvue IPO

TL;DR

<b>Johnson & Johnson has submitted its 2023 10-K filing, detailing financial performance and corporate events for the fiscal year ending December 31, 2023.</b>

AI Summary

JOHNSON & JOHNSON (JNJ) filed a Annual Report (10-K) with the SEC on February 16, 2024. Johnson & Johnson filed its 2023 Form 10-K on February 16, 2024, for the fiscal year ending December 31, 2023. The filing covers the period from January 2, 2023, to December 31, 2023. Key financial statement members such as Common Stock, Retained Earnings, and Accumulated Other Comprehensive Income are detailed for the fiscal years 2021, 2022, and 2023. The company's fiscal year ends on December 31. The filing includes information related to the IPO of Kenvue Inc. on May 8, 2023.

Why It Matters

For investors and stakeholders tracking JOHNSON & JOHNSON, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Johnson & Johnson's financial health and operational activities for the past fiscal year, crucial for investors to assess performance and future outlook. The inclusion of details regarding the Kenvue Inc. IPO offers insight into significant corporate restructuring and value realization events undertaken by the company.

Risk Assessment

Risk Level: low — JOHNSON & JOHNSON shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant new risks or disclosures beyond routine updates.

Analyst Insight

Review the detailed financial statements and segment information within the 10-K to understand Johnson & Johnson's performance across its business segments and identify any emerging trends or risks.

Key Numbers

Key Players & Entities

FAQ

When did JOHNSON & JOHNSON file this 10-K?

JOHNSON & JOHNSON filed this Annual Report (10-K) with the SEC on February 16, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by JOHNSON & JOHNSON (JNJ).

Where can I read the original 10-K filing from JOHNSON & JOHNSON?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by JOHNSON & JOHNSON.

What are the key takeaways from JOHNSON & JOHNSON's 10-K?

JOHNSON & JOHNSON filed this 10-K on February 16, 2024. Key takeaways: Johnson & Johnson filed its 2023 Form 10-K on February 16, 2024, for the fiscal year ending December 31, 2023.. The filing covers the period from January 2, 2023, to December 31, 2023.. Key financial statement members such as Common Stock, Retained Earnings, and Accumulated Other Comprehensive Income are detailed for the fiscal years 2021, 2022, and 2023..

Is JOHNSON & JOHNSON a risky investment based on this filing?

Based on this 10-K, JOHNSON & JOHNSON presents a relatively low-risk profile. The filing is a standard annual report (10-K) and does not contain immediate, significant new risks or disclosures beyond routine updates.

What should investors do after reading JOHNSON & JOHNSON's 10-K?

Review the detailed financial statements and segment information within the 10-K to understand Johnson & Johnson's performance across its business segments and identify any emerging trends or risks. The overall sentiment from this filing is neutral.

How does JOHNSON & JOHNSON compare to its industry peers?

Johnson & Johnson operates in the pharmaceutical and healthcare industries, a sector characterized by significant research and development, regulatory oversight, and global market dynamics.

Are there regulatory concerns for JOHNSON & JOHNSON?

The pharmaceutical industry is heavily regulated by bodies like the FDA, requiring strict adherence to manufacturing, safety, and marketing standards. Filings like the 10-K are mandated by the SEC under the Securities Exchange Act of 1934.

Industry Context

Johnson & Johnson operates in the pharmaceutical and healthcare industries, a sector characterized by significant research and development, regulatory oversight, and global market dynamics.

Regulatory Implications

The pharmaceutical industry is heavily regulated by bodies like the FDA, requiring strict adherence to manufacturing, safety, and marketing standards. Filings like the 10-K are mandated by the SEC under the Securities Exchange Act of 1934.

What Investors Should Do

  1. Analyze the financial statements for revenue trends, profitability, and balance sheet strength.
  2. Examine disclosures related to the Kenvue Inc. IPO and its impact on Johnson & Johnson's financial structure.
  3. Review any risk factors or management discussion sections for insights into operational challenges and strategic priorities.

Key Dates

Year-Over-Year Comparison

This filing is the annual 10-K report for the fiscal year 2023, providing a year-end summary compared to previous periods.

Filing Stats: 4,279 words · 17 min read · ~14 pages · Grade level 19.7 · Accepted 2024-02-16 16:12:22

Key Financial Figures

Filing Documents

Signatures

Signatures 116 Exhibit i ndex 118 Cautionary note regarding forward-looking statements This Annual Report on Form 10-K and Johnson & Johnson's other publicly available documents contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson & Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. Forward-looking statements do not relate strictly to historical or current facts and reflect management's assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives, including associated cost savings and other benefits; the Company's strategy for growth; product development activities; regulatory approvals; market position and expenditures. Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company's control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company's actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to: Risks related to product development, market success and competition Ch

Business

Item 1. Business General Johnson & Johnson and its subsidiaries (the Company) have approximately 131,900 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson & Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company's primary focus is products related to human health and well-being. Johnson & Johnson was incorporated in the State of New Jersey in 1887. The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's two business segments: Innovative Medicine (previously referred to as Pharmaceutical) and MedTech. Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located. Segments of business Following the completion of the separation of the Consumer Health business (Kenvue) in August 2023, the Company is now organized into two business segments: Innovative Medicine and MedTech. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: Item 7. Management's discussion and analysis of results of operations and financial condition of this Report; and Note 17 Segments of business and geographic areas of the notes to consolidated financial statements included in Item 8 of this Report. Innovative Medicine The Innovative Medicine segment is focused on the following therapeutic areas: Immunology (e.g., rheumatoid arthritis, psoriatic arthr

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing